Oncology | Phase II Developments | FRANCE

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Innate Pharma to Present New Efficacy Data For Monalizumab in Combination With Cetuximab in Head And Neck cancer at The ASCO20

Lead Product(s): Monalizumab,Cetuximab

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Darolutamide significantly reduced risk of death by 31% in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE).

MAbSilico solutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

OSE Immunotherapeutics Partners with MAbSilico

Lead Product(s): Tedopi,Nivolumab

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 12, 2020

Details:

Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform).

IMMUTEP SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Immutep to Present TACTI-002 Interim Data at German Cancer Congress

Lead Product(s): Eftilagimod Alpha

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

The data relates to use of the company’s lead product candidate eftilagimod alpha, as part of a combination treatment with pembrolizumab.

Cellectis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Iovance Biotherapeutics to license certain TALEN technology from Cellectis

Lead Product(s): Tumor infiltrating lymphocytes

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Iovance Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Iovance Biotherapeutics will use TALEN® Technology from Cellectis to develop Gene-Edited TIL that have been genetically edited to create more potent cancer therapeutics.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Innate Pharma will take the operational measures to reactivate the lacutamab TELLOMAK trial in Sézary syndrome and MF in France and UK, where regulatory agencies have authorized it.